Delivery Order SPE2DB24D6044-SPE2DB25FLHFB

Award Date 1/3/25
Potential Completion Date 1/6/25
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $2,007.04, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of EMGALITY 120 MG/ML PENML, a pharmaceutical product, with an ultimate completion date of December 9, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,729.00, is for the supply of EMGALITY 120 MG/ML PENML, a specialty medication. The contract has a firm fixed price pricing type and an ultimate completion date of December 2, 2024. This delivery order is a part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of EMGALITY 120 MG/ML PENML, a specialty medication. The contract has a ceiling value of $1,868.28 and an ultimate completion date of March 17, 2022. This award is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,731.84, is for the delivery of EMGALITY 120 MG/ML PENML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order with a completion date of September 17, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of EMGALITY 120 MG/ML PENML, a prescription medication. The firm-fixed-price contract has a ceiling value of $1,002.72 and a period of performance through August 8, 2024. This award is not associated with a set-aside program. Amerisourcebergen holds several Indefinite Delivery Contracts (IDCs) with DLA and other federal...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of EMGALITY 120 MG/ML PENML medication. The contract is a firm fixed-price, Indefinite Delivery Contract (IDC) with a ceiling value of $1,671.20 and an ultimate completion date of August 9, 2024. The award does not have a set-aside designation. Amerisourcebergen, through its corporate office division, will provide the medication to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,192.26 firm fixed-price delivery order is for the supply of EMGALITY 120 MG/ML PENML, a specialty medication. The contract has an ultimate completion date of November 19, 2024 and was awarded on November 18, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,729 firm-fixed-price delivery order is for the supply of EMGALITY 120 MG/ML PENML, a prescription medication. The contract has an ultimate completion date of November 29, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $1,729, is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of December 31, 2024. The contract is for the provision of EMGALITY 120 MG/ML PENML, a pharmaceutical product. This award is not designated as a set-aside. Amerisourcebergen holds...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,011.52 Firm Fixed Price Delivery Order contract is for the supply of EMGALITY 120 MG/ML PENML, a prescription medication. The contract has an ultimate completion date of September 25, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
  • SPE2DB24D6044
    Indefinite Delivery Contract
  • SPE2DB24D6044-SPE2DB25FLHFB
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of EMGALITY 120 MG/ML PENML, a medical product, with a ceiling value of $2,906.88 and a completion date of January 6, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 4/6/25, 12:42 AM